Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 52-56, 2019.
Article
Dans Chinois
| WPRIM
| ID: wpr-772331
ABSTRACT
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Imagerie diagnostique
/
Résultat thérapeutique
/
Issue fatale
/
Carcinome pulmonaire non à petites cellules
/
Évolution de la maladie
/
Résistance aux médicaments antinéoplasiques
/
Utilisations thérapeutiques
/
Inhibiteurs de protéines kinases
/
Traitement médicamenteux
/
Récepteurs ErbB
Type d'étude:
Etude diagnostique
Limites du sujet:
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Chinese Journal of Lung Cancer
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS